STD Specialists Warn of Shortage of Vital Syphilis Drug

Follow Drugslib on

Medically reviewed by Drugs.com.

By Ernie Mundell HealthDay Reporter

MONDAY, Dec. 4, 2023 -- As syphilis cases surge across America, a group representing the nation's STD specialists says members are reporting shortages of a drug essential to fighting the disease.

In a survey from the National Coalition of STD Directors conducted in early November, 46% of sexual health clinics said they'd tried to order Bicillin L-A -- only to find that it was unavailable.

Bicillin L-A, a form of penicillin, is crucial to the treatment of syphilis. That's especially true for congenital syphilis, which occurs when a newborn contracts the illness from an infected mother.

Early in November, the U.S. Centers for Disease Control and Prevention sounded the alarm on the disease, noting that rates of congenital syphilis soared 10-fold between 2012 and 2022.

In 2022, more than 3,700 babies across the United States were born with syphilis, the CDC said.

According to the March of Dimes, "If not treated right away, congenital syphilis can cause problems for your baby later in life," including deformities of the bones and teeth, paralysis or seizures, problems with vision and hearing and developmental delays.

Luckily, Bicillin L-A can quickly vanquish the syphilis bacterium. It's the only treatment approved for pregnant women with syphilis, and it's also the first-line therapy for syphilis patients generally.

Bicillin L-A is made by Pfizer Inc., which in June alerted the U.S. Food and Drug Administration of a shortage that the company predicts may last until mid-2024.

The new survey confirms that Bicillin L-A is in short supply nationwide.

The group sent its survey to 136 state and local health departments and 151 sexual health clinics in early November.

Among the findings:

  • Respondents in 13 different states and one Indian Health Services agency said they'd received reports of at least one pregnant woman who'd been unable to receive Bicillin L-A
  • Nearly half (46%) of clinics said they'd had difficulties getting Bicillin L-A, a increase from the 40% of clinics who hadn't been able to access the drug when a prior survey was conducted in August
  • More than two-thirds (68%) of health department specialists believe shortages will cause syphilis cases to rise even higher in their jurisdictions

    • There is a second-line treatment, doxycycline, which patients can use if Bicillin L-A is not available. But treatment can take a month and severe side effects can occur.

    In the new survey, 36% of clinics said they'd had a patient who could not complete their full course of doxycycline.

    The CDC has already advised that, to preserve supply, doctors use Bicillin L-A only for cases of congenital syphilis and give doxycycline to all other patients.

    Sources

  • National Coalition of STD Directors, news release, Nov. 30, 2023

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2023-12-04 20:36

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords